Results 11 to 20 of about 1,620,216 (383)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer [PDF]

Cancer Metastasis Review, 2021
Immunotherapy has become a mainstay of cancer treatment in many malignancies, though its application in breast cancer remains limited. Of the breast cancer subtypes, triple-negative breast cancers (TNBCs) are characterized by immune activation and ...
Arielle L. Heeke, Antoinette R. Tan
openalex   +2 more sources

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Nature Medicine, 2023
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing ( n  = 72,
F. Mosele, É. Deluche, A. Lusque, Loïc Le Bescond, T. Filleron, Yoann Pradat, A. Ducoulombier, B. Pistilli, T. Bachelot, F. Viret, C. Lévy, N. Signolle, Alexia Alfaro, D. Tran, I. Garberis, H. Talbot, S. Christodoulidis, M. Vakalopoulou, N. Droin, A. Stourm, Maki Kobayashi, T. Kakegawa, L. Lacroix, P. Saulnier, B. Job, Marc Deloger, M. Jimenez, C. Mahier, Vianney Baris, Pierre Laplante, P. Kannouche, V. Marty, M. Lacroix-Triki, V. Diéras, F. André   +34 more
semanticscholar   +1 more source

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

New England Journal of Medicine, 2021
Copyright © 2021 Massachusetts Medical Society. BACKGROUND Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell ...
A. Bardia, S. Hurvitz, S. Tolaney, D. Loirat, K. Punie, Mafalda Oliveira, A. Brufsky, S. Sardesai, K. Kalinsky, A. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortés, J. O’Shaughnessy, V. Diéras, C. Ferrario, P. Schmid, L. Carey, L. Gianni, M. Piccart, S. Loibl, D. Goldenberg, Q. Hong, M. Olivo, L. Itri, H. Rugo   +29 more
semanticscholar   +1 more source

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

JAMA Oncology, 2022
Key Points Question Can tucatinib, trastuzumab, and capecitabine provide systemic and intracranial benefit for patients with ERBB2 (HER2)-positive metastatic breast cancer and brain metastases?
N. Lin, R. Murthy, V. Abramson, C. Anders, T. Bachelot, P. Bedard, V. Borges, D. Cameron, L. Carey, A. J. Chien, G. Curigliano, M. DiGiovanna, K. Gelmon, G. Hortobagyi, S. Hurvitz, I. Krop, S. Loi, S. Loibl, V. Mueller, Mafalda Oliveira, E. Paplomata, M. Pegram, D. Slamon, A. Zelnak, J. Ramos, W. Feng, Eric P. Winer   +26 more
semanticscholar   +1 more source

Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases [PDF]

PeerJ, 2019
Background Reports on the incidence and prognoses of lung metastases when diagnosing breast cancer patients with different subtypes are limited. Our study investigated the effect of molecular sub-typing stratification on the prognoses of lung metastatic ...
Siying Chen, Jin Yang, Yang Liu, Haisheng You, Yalin Dong, Jun Lyu   +5 more
doaj   +2 more sources

Acute urine retention following medullary compression of metastatic breast cancer in the spinal cord: Rare symptomatlogic presentation and management

Radiology Case Reports, 2023
The management of locally advanced and metastatic breast cancer has evolved since 2021, with confirmation of the role of cell cycle inhibitors.The discovery of breast cancer is often the result of self-examination through the discovery of a nodule, but ...
Hammou El Farhaoui, Anouar El Moudane, Hanane Al Aggari, Miry Nadir, Oualid Bounouar, Ali Barki   +5 more
doaj   +1 more source

Comparisons of Metastatic Patterns, Survival Outcomes and Tumor Immune Microenvironment Between Young and Non-Young Breast Cancer Patients

Frontiers in Cell and Developmental Biology, 2022
Background: Metastases are the main cause of breast cancer-related deaths. Breast cancer has a more aggressive phenotype and less favorable prognosis in young females than in older females.
Hengwen Sun, Wei Huang, Fei Ji, Yi Pan, Lu Yang   +4 more
doaj   +1 more source

Breast surgery for metastatic breast cancer [PDF]

Cochrane Database of Systematic Reviews, 2014
Metastatic breast cancer is not a curable disease, but women with metastatic disease are living longer. Surgery to remove the primary tumour is associated with an increased survival in other types of metastatic cancer. Breast surgery is not standard treatment for metastatic disease, however several recent retrospective studies have suggested that ...
Giuliano, Tosello, Maria Regina, Torloni, Bruna S, Mota, Teresa, Neeman, Rachel, Riera   +4 more
openaire   +2 more sources

Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer

Nature Communications, 2021
Molecular profiling of circulating extracellular vesicles (EVs) provides a promising noninvasive means to diagnose, monitor, and predict the course of metastatic breast cancer (MBC).
Fei Tian, Shaohua Zhang, Chao Liu, Ziwei Han, Yuan Liu, Jinqi Deng, Yike Li, Xia Wu, Lili Cai, Lili Qin, Qinghua Chen, Yang Yuan, Yi Liu, Y. Cong, Baoquan Ding, Zefei Jiang, Jiashu Sun   +16 more
semanticscholar   +1 more source

The Metabolic Mechanisms of Breast Cancer Metastasis

Frontiers in Oncology, 2021
Breast cancer is one of the most common malignancy among women worldwide. Metastasis is mainly responsible for treatment failure and is the cause of most breast cancer deaths.
Lingling Wang, Lingling Wang, Shizhen Zhang, Xiaochen Wang   +3 more
doaj   +1 more source